Lawmakers in Rhode Island are expected to vote on cannabis policy reform this week, with legislative committees in the state Senate and House of Representatives scheduled to consider identical bills to legalize recreational pot for adults.  The Senate Judiciary Committee will vote on Senate Bill 2430 sponsored by Democratic... Read more
In what is absolutely a sign that the new interest in psychedelic drugs has landed on the other side of The Pond, a new commercial facility has opened for trials in London. Clerkenwell Health, a British start-up, will begin trials of psilocybin to help terminal patients manage the anxiety... Read more
The U.S. Food and Drug Administration (FDA) once again cautioned people to keep their edibles out of reach from children, especially the ones with sketchy, colorful packaging that might appeal to children. On May 13, the FDA issued a warning, sounding the alarm about lookalike products that mimic candy... Read more
A new comprehensive study of more than 1,000 people has confirmed the safety of orally-ingested cannabidiol products and provides data that addresses the U.S. Food and Drug Administration’s concerns about the safety of CBD. The two-part study found that daily consumption of CBD across a range of typical retail... Read more
The Campaign for Sensible Cannabis Laws is a nonpartisan organization that is striving to “reform Iowa’s medical and recreational cannabis laws based on fairness, financial prudence, and common sense.” The group recently launched its newest campaign, which is led by Bradley Knott and Pete D’Alessandro. Recently, Knott authored an... Read more
Broadens Canopy Growth’s Portfolio of Premium Brands with Significant Opportunities to Scale Across North America SMITHS FALLS, ON and OAKLAND, Calif., May 18, 2022 /PRNewswire/ – Canopy Growth Corporation (“Canopy Growth” or “the Company”) (TSX: WEED) (NASDAQ: CGC) and Lemurian, Inc. (“Jetty”), a California-based producer of high-quality cannabis extracts... Read more
Revenue Increases 64% to $31.8 Million Compared to $19.3 Million in Q1 2021 Adjusted EBITDA is $7.9 Million, 25% of Revenue 14 Dispensaries Added During Q1 2022 in Colorado and New Mexico On Track to Achieve GuidanceQ4 2022 Projected Revenue Annualized Run Rate of Approximately $220 Million – $260 MillionQ4 2022 Projected Adjusted EBITDA Annualized Run Rate of Approximately $70 Million – $82... Read more
Sale Leaseback Transactions with IIPR include Massachusetts and Pennsylvania Facilities Net Proceeds from Both Transactions Expected to Reduce Existing Debt by up to 50% PHOENIX, May 16, 2022 (GLOBE NEWSWIRE) — TILT Holdings Inc. (“TILT” or the “Company”) (NEO: TILT) (OTCQX: TLLTF), a global provider of cannabis business solutions... Read more
Omni-channel retail revenue increased 97% year-over-year, comprising 57% of net sales in Q1 2022 Gross margin improved to 25% in Q1 2022 from 12% average in 2021 Reveals strategic business improvement initiatives to support long-term profitability Announces FY 2022 expected operating expense savings of $30M, a reduction of 20%... Read more
Company reports 20% year-over-year revenue growth and 45% year-over-year adjusted EBITDA1 growth – and continues industry leadership in branded wholesale and retail productivity Clears first milestone in proposed Columbia Care transaction with expiration of 30-day HSR2 review period CHICAGO-May 18, 2022-(BUSINESS WIRE)–Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco... Read more



( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )